A real-world evidence study examining COVID-19 pandemic disruptions in osteoporosis care patterns and outcomes across Alberta, Canada, was presented through two posters at the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases
Alzheimer’s disease (AD) is a degenerative neurological disease with progressive death of brain cells, eventually leading to death.1,2 It is the most prevalent irreversible dementia, marked by deterioration of memory, judgement, and reasoning and worsening of mood, behaviour, communication, and function to perform daily activities.1 With longer life expectancy and an aging population, the burden of AD on the quality of life of patients and their family and caregivers is increasing.
With National Indigenous People’s Day on June 21st, Medlior is reflecting on health disparities for Indigenous peoples in Canada. First Nations, Inuit, and Métis people have typically been underrepresented in research studies, but there are promising signs of change.
Approximately 1 in 12 Canadians, mostly children, are affected by a rare disorder. Patients with rare diseases face many challenges, including misdiagnosis, limited treatment, and difficulty accessing innovative therapies even when they are available. Implementing the Rare Disease Strategy will not necessarily cost Canadians more. Earlier diagnosis and correct treatments can lead to reduced unnecessary surgeries, organ transplants, and visits to multiple specialists, resulting in savings for the health system and taxpayers.
Reflecting over the last 2 years The pandemic has shown us the crucial imperative of having highly functioning and interconnected healthcare systems. Everything comes at a cost which is why it is so important to achieve the greatest value for money. But what is value...
Following the unprecedented year of 2020, 2021 brought increased global awareness to our field of work. The pandemic has brought terms such as ‘epidemiology’, ‘efficacy’ and ‘real word evidence’ into lay language and the vital role of health outcomes research has...
As the reality of living amongst a global pandemic set in across the world over the past year, a key highlight of 2021 was undoubtedly the rollout of life saving vaccines from AstraZeneca, Pfizer, Johnson and Johnson, and Moderna. At Medlior, this was also a year of...
Dr. Shaun Goodman, from the Division of Cardiology, St. Michael's Hospital, Toronto, Ontario, and Canadian VIGOUR Centre, University of Alberta, Edmonton, Alberta, presented a poster at the 2021 Scientific Sessions American Heart Association Virtual Conference...
A real-world evidence study focusing on the burden of Huntington’s disease (HD) in Alberta, was presented at the virtual 28thAnnual Meeting of the Huntington Study Group (HSG) from November 4-6, 2021. This study was conducted by Medlior on behalf of Hoffmann-La Roche....
On March 11, 2020, the World Health Organization made the announcement that the coronavirus-2019 (COVID-19) was officially characterized as a pandemic.1 As many healthcare resources were redeployed or redistributed to address the acute need of COVID-19, large impacts...
